- Home
- URGN vs NPFD Comparison
URGN vs NPFD Comparison
Compare URGN & NPFD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- URGN
- NPFD
- Stock Information
- Founded
- URGN 2004
- NPFD 2021
- Country
- URGN United States
- NPFD United States
- Employees
- URGN N/A
- NPFD N/A
- Industry
- URGN Biotechnology: Pharmaceutical Preparations
- NPFD Trusts Except Educational Religious and Charitable
- Sector
- URGN Health Care
- NPFD Finance
- Exchange
- URGN Nasdaq
- NPFD Nasdaq
- Market Cap
- URGN 465.9M
- NPFD 453.8M
- IPO Year
- URGN 2017
- NPFD N/A
- Fundamental
- Price
- URGN $10.08
- NPFD $19.10
- Analyst Decision
- URGN Strong Buy
- NPFD
- Analyst Count
- URGN 6
- NPFD 0
- Target Price
- URGN $42.25
- NPFD N/A
- AVG Volume (30 Days)
- URGN 308.1K
- NPFD 64.7K
- Earning Date
- URGN 03-13-2025
- NPFD 01-01-0001
- Dividend Yield
- URGN N/A
- NPFD 6.28%
- EPS Growth
- URGN N/A
- NPFD N/A
- EPS
- URGN N/A
- NPFD N/A
- Revenue
- URGN $89,363,000.00
- NPFD N/A
- Revenue This Year
- URGN $12.17
- NPFD N/A
- Revenue Next Year
- URGN $44.23
- NPFD N/A
- P/E Ratio
- URGN N/A
- NPFD N/A
- Revenue Growth
- URGN 15.64
- NPFD N/A
- 52 Week Low
- URGN $9.78
- NPFD $14.50
- 52 Week High
- URGN $20.70
- NPFD $18.07
- Technical
- Relative Strength Index (RSI)
- URGN 40.55
- NPFD 53.51
- Support Level
- URGN $9.86
- NPFD $19.05
- Resistance Level
- URGN $11.87
- NPFD $19.22
- Average True Range (ATR)
- URGN 0.50
- NPFD 0.15
- MACD
- URGN -0.04
- NPFD -0.01
- Stochastic Oscillator
- URGN 10.95
- NPFD 29.55
About URGN UroGen Pharma Ltd.
UroGen Pharma Ltd is a clinical-stage biotechnology firm specializing in innovative solutions for urothelial and specialty cancers. The company has developed RTGel reverse-thermal hydrogel, a proprietary technology enhancing the therapeutic profiles of existing drugs by enabling sustained release. Their flagship product, Jelmyto (mitomycin) for pyelocalyceal solution, along with investigational candidate UGN-102 (mitomycin) for intravesical solution, targets non-surgical tumor ablation in forms of non-muscle invasive urothelial cancer. Additionally, their immuno-uro-oncology pipeline includes UGN-301 (zalifrelimab), an anti-CTLA-4 antibody, intended for both monotherapy and combination therapy. Revenue is generated from product sales.
About NPFD Nuveen Variable Rate Preferred & Income Fund
Nuveen Variable Rate Preferred&Income is a newly organized, diversified, closed-end management investment company. The Fund's investment objective is to seek to provide a high level of current income and total return.